The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Open accessAbstract
The continued emergence of Middle East Respiratory Syndrome (MERS) cases with a high case fatality rate stresses the need for the availability of effective antiviral treatments. Remdesivir (GS-5734) effectively inhibited MERS coronavirus (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS)-CoV in a mouse model. Here, we tested the efficacy of prophylactic and therapeutic remdesivir treatment in a nonhuman primate model of MERS-CoV infection, the rhesus macaque. Prophylactic remdesivir treatment initiated 24 h prior to inoculation completely prevented MERS-CoV−induced clinical disease, strongly inhibited MERS-CoV replication in respiratory tissues, and prevented the formation of lung lesions. Therapeutic remdesivir treatment initiated 12 h postinoculation also provided a clear clinical benefit, with a reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions. The data presented here support testing of the efficacy of remdesivir treatment in the context of a MERS clinical trial. It may also be considered for a wider range of coronaviruses, including the currently emerging novel coronavirus 2019-nCoV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Self-citationA Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Self-citationTherapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAssiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Self-citationRiou, J., & Althaus, C. L. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.4.2000058 · Cited by 1,297
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
Corman, V. M., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bludau, M., van Boheemen, S., Gopal, R., Ballhause, M., Bestebroer, T. M., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.39.20285-en · Cited by 561
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Lo, M. K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D., Clarke, M. O., et al. (2017) · Scientific Reports · doi:10.1038/srep43395 · Cited by 513
Self-citationHui, D. S., Azhar, E. I., Kim, Y.-J., Memish, Z. A., Oh, M.-D., & Zumla, A. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30127-0 · Cited by 448
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Self-citationLate Ebola virus relapse causing meningoencephalitis: a case report
Jacobs, M., Rodger, A., Bell, D. J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R. J., Hopkins, S., Hughes, J., Jabeen, F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30386-5 · Cited by 361
de Wit, E., Rasmussen, A. L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D. L., Fischer, E. R., Martellaro, C., Okumura, A., Chang, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310744110 · Cited by 313
Self-citationRemdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
Lo, M. K., Feldmann, F., Gary, J. M., Jordan, R., Bannister, R. M., Cronin, J., Patel, N. R., Klena, J. D., Nichol, S. T., Cihlář, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9242 · Cited by 293
Self-citationInfection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset
Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A. L., Okumura, A., Peng, X., Thomas, M. J., van Doremalen, N., Haddock, E., Nagy, L., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004250 · Cited by 210
Self-citationBin, S. Y., Heo, J. Y., Song, M.-S., Lee, J., Kim, E.-H., Park, S.-J., Kwon, H.-I., Kim, S. M., Kim, Y.-I., Si, Y.-J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1020 · Cited by 190
First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease
Dörnemann, J., Burzio, C., Ronsse, A., Sprecher, A., Clerck, H. D., Herp, M. V., Kolié, M.-C., Yosifiva, V., Caluwaerts, S., McElroy, A. K., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw493 · Cited by 138
CEPI—a new global R&D organisation for epidemic preparedness and response
Brende, B., Farrar, J., Gashumba, D., Moedas, C., Mundel, T., Shiozaki, Y., Vardhan, H., Wanka, J., & Røttingen, J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30131-9 · Cited by 114
Al-Abdely, H. M., Midgley, C. M., Alkhamis, A. M., Abedi, G. R., Lu, X., Binder, A. M., Alanazi, K. H., Tamin, A., Banjar, W. M., Lester, S. N., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2504.181595 · Cited by 87
Chen, Z., Bao, L., Chen, C., Zou, T., Xue, Y., Li, F., Lv, Q., Gu, S., Gao, X., Cui, S., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix209 · Cited by 78
van Doremalen, N., Falzarano, D., Ying, T., de Wit, E., Bushmaker, T., Feldmann, F., Okumura, A., Wang, Y., Scott, D. P., Hanley, P. W., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.03.025 · Cited by 64
Self-citationModjarrad, K., Moorthy, V., Embarek, P. B., Kerkhove, M. D. V., Kim, J. H., & Kiény, M.-P. (2016) · Nature Medicine · doi:10.1038/nm.4131 · Cited by 60
Pathogenicity and Viral Shedding of MERS-CoV in Immunocompromised Rhesus Macaques
Prescott, J. B., Falzarano, D., de Wit, E., Hardcastle, K., Feldmann, F., Haddock, E., Scott, D. P., Feldmann, H., & Munster, V. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00205 · Cited by 52
Self-citationProphylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets
de Wit, E., Feldmann, F., Okumura, A., Horne, E. J., Haddock, E., Saturday, G. A., Scott, D. P., Erlandson, K. J., Stahl, N., Lipsich, L. A., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.06.006 · Cited by 33
Self-citation
Cited by
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06022-5 · Cited by 2,105
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Metadata
- Authors
- de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2020-02-13
- Volume
- 117
- Issue
- 12
- Pages
- 6771-6776
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3006564542
- Cited by
- 887
- References
- 25
- FWCI
- 25.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.